Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).

Abstract

Laron syndrome (LS, congenital primary GH insensitivity) is caused by deletions or mutations in the GH receptor gene, resulting in an inability to generate insulin-like growth factor-I (IGF-I). If untreated, the deficiency of IGF-I results in severe dwarfism, as well as skeletal and muscular underdevelopment. The only treatment is the daily administration of recombinant IGF-I. This review summarizes the present experience by several groups worldwide. The main conclusions are: A. The one or two injections regimen result in the same growth velocity; B. The growth velocity obtained with IGF-I administration is smaller than that observed with hGH in children with congenital isolated GH deficiency; C. Overdosage of IGF-I causes a series of adverse effects which can be avoided by carefully monitoring the serum IGF-I and GH levels.

• Authors: Zvi Laron
• Journal: Pediatric endocrinology reviews : PER (Pediatr Endocrinol Rev) Vol. 5 Issue 3 Pg. 766-71 (Mar 2008) ISSN: 1565-4753 [Print] Israel
• PMID: 18367997 (Publication Type: Journal Article, Review)

Chemical References

• Insulin-Like Growth Factor I

Topics

• Child
• Humans
• Insulin-Like Growth Factor I (therapeutic use)
• Laron Syndrome (drug therapy)